Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Newamsterdam Pharma B V (Dutch Registration No 55971946) is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The data shows that prosecution activity is limited to 1 distinct examiner and 1 distinct art unit. This indicates a narrow focus for the company's current patent filings with all active matters localized in one technical area.
The busiest examiner identified is SIMMONS, CHRIS E, who is assigned 1 busiest examiner pending office action. Since the portfolio only contains 1 distinct examiner, SIMMONS, CHRIS E is managing the full extent of the company's pending actions. This creates a direct link between the examiner's specific standards and the company's overall prosecution success.
The 1 distinct art unit involved suggests that the technical review is confined to a single specialized group. The 1 pending office action represents the total current administrative burden for the company's portfolio. This focused profile suggests that the company is managing a specific set of claims under the oversight of 1 distinct examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SIMMONS, CHRIS E | 1 | 34.2% | +19.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17873009 | TREATMENT OF HIS HYPORESPONDERS | SIMMONS, CHRIS E | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17873009 | TREATMENT OF HIS HYPORESPONDERS | SIMMONS, CHRIS E | 1622 | §103 | Final Rejection | — | Pending | Jul 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNewamsterdam Pharma B V (Dutch Registration No 55971946) has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Chris E Simmons has the most, with 1 of Newamsterdam Pharma B V (Dutch Registration No 55971946)'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
